Deals channel feed – Endpoints News

Deals channel feed

Amgen kicks off 2023 dealmaking with busy ADC upstart Synaffix

3 years ago

WuXi inks $1.5B GSK pact, a big biobuck bet but a blip in billions lost from US unverified list

3 years ago

Ginkgo joins Esperovax to attempt RNA cancer treatment — in a pill

3 years ago

Carmell Therapeutics plans SPAC deal with Alpha Healthcare, bypassing IPO

3 years ago

On the road to human studies, next-gen gene editing contender Metagenomi hauls in an extra $100M

3 years ago

Sesen Bio pushes back after investor group attacks merger as ‘illogical’

3 years ago

Hummingbird and Synaffix agree to antibody-drug conjugate deal worth up to $150M

3 years ago

Capsida makes $55M deal with Eli Lilly to develop gene therapies

3 years ago

Moderna's globetrotting BD team snags an mRNA upstart with some handy new tech tools

3 years ago

After disastrous Galapagos deal, Gilead finds new rheumatoid arthritis partner

3 years ago

Forge spinoff Blacksmith Medicines merges back into company two years after launch, but details are slim

3 years ago

Updated: US puts hold on F-star's takeover by China’s Sino Biopharm, citing national security risks

3 years ago

With focus on neglected eye diseases, Opus buys two gene therapies from Iveric Bio

3 years ago

Gilead buys out cash-hungry partner Jounce's antibody for $67M

3 years ago

Stifel Financial swallows life sciences investment bank Torreya Partners

3 years ago

Vaxcyte makes deal with Sutro Biopharma to take over manufacturing of vaccine component

3 years ago

Vistagen acquires Pherin Pharmaceuticals for 12.4M shares and 'nominal' cash

3 years ago

Berkeley Lights to acquire IsoPlexis in $57.8M all-stock deal

3 years ago

Eli Lilly ties up 2022 by expanding deal with battered RNA-editing biotech

3 years ago

Back again: Merck willing to dole out more than $9B for Kelun’s ADCs

3 years ago

Zymeworks sings to the tune of $325M with Jazz opt-in for HER2 cancer drug

3 years ago

HealthCare Royalty pays Atara $31M cash for a piece of cell therapy royalties in Europe

3 years ago

After PhII results disappoint, Merck excises eye drugs from longtime pact with NGM

3 years ago

Catalyst Pharmaceuticals to acquire commercial rights to an Eisai seizure medication for $160M

3 years ago

First page Previous page 43 44 454647 48 49 Next page Last page